New combo tackles tough myeloma in early trial
NCT ID NCT03702725
First seen Jan 10, 2026 · Last updated May 19, 2026 · Updated 15 times
Summary
This early-phase study tested a three-drug combination (ibrutinib, lenalidomide, and dexamethasone) in 14 people whose multiple myeloma had returned or stopped responding to treatment. The main goal was to find safe doses and identify side effects. While the approach aims to control the disease, it is not a cure, and ongoing treatment is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Ohio State University Wexner Medical Center/James Cancer Hospital
Columbus, Ohio, 43210, United States
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.